Celldex Differentiated Immuno-Oncology Asset Ripe For Combos
This article was originally published in Pharmaceutical Approvals Monthly
Celldex Therapeutics will initiate Phase I/II trials of its immunotherapy varlilumab in combination with Bristol’s PD-1 inhibitor nivolumab this year and is exploring multiple other combinations.
You may also be interested in...
All on its own, Celldex is gearing up to run a Phase III trial in the second half of 2011, testing its therapeutic cancer vaccine rindopepimut in newly diagnosed glioblastoma, after releasing positive results from ACT III, the last of three trials in its Phase II program.
Antibody-drug conjugates remain a hot area of cancer drug development and Pfizer showed investors some of the novel targets and improved payloads it is advancing.
The company showcased its expanded cancer drug pipeline two months after completing the acquisition of Seagen last year.